Web Results


Sanofi India Limited, headquartered in Mumbai, is a part of Sanofi group. Sanofi SA and its wholly owned subsidiary Hoechst AG, are the major shareholders of Sanofi India Limited. Its manufacturing portfolio contains medicines for several therapeutic areas including cardiovascular, thrombotic, metabolic disorders, ...


Company Information. Industry; Pharmaceuticals; Therapeutic Areas; Non- Specific; Alias(es); Ownership; Private; Headquarters; Worldwide. Europe. Western Europe. France. Parent & Subsidiaries; Sanofi · Aventis SA · Aventis Pharma France SA · Gencell SA. Senior Management; Contact Info; Aventis Pharma France SA


Sep 5, 2017 ... Find Sanofi US corporate information, pharmaceutical products, news, career opportunities and health resources.


AVENTIS PHARMA, S.A.. Basada en una investigación internacional, la actividad de sanofi-aventis se concentra en siete importantes áreas terapéuticas: cardiovascular, trombosis, oncología, enfermedades metabólicas, sistema nervioso central, medicina interna y vacunas. Sanofi-av. MARCAS: sanofi-aventis  ...


Welcome to Sanofi in South Africa website. Find out information on the company, diseases we treat, jobs and press releases.


Jul 26, 2012 ... Cipla Medpro (Pty) Ltd v Aventis Pharma SA, Aventis Pharma SA and Others v Cipla Life Sciences (Pty) Ltd and Others (139/2012, 138/2012) [2012] ZASCA 108; 2013 (4) SA 579 (SCA) (26 July 2012) ...



Inicio · Índice de Laboratorios; AVENTIS PHARMA, S.A.. AVENTIS PHARMA, S.A. . Medicamentos · BELUSTINE Cáps. Páginas visitadas recientemente. Los productos de Vademecum. Vademecum Internacional 2017 ESPAÑA (eBook). La edición 2017 ya disponible. Vidal Vademecum MÉXICO 2017 (eBook). La edición ...


May 26, 2008 ... By Donald Zuhn -- Earlier this month, the Federal Circuit in a 2-1 decision affirmed the determination by the District Court for the Central District of California that U.S. Patent Nos. RE 38743 and 5389618, which are owned by Plaintiffs- Appellees Aventis Pharma S.A. and Aventis Pharmaceuticals, Inc.